Rexulti Starting Dose for Depression
The recommended starting dose of Rexulti (brexpiprazole) for major depressive disorder is 0.5 mg or 1 mg orally once daily, with titration to the target dose of 2 mg once daily over weekly intervals.
Dosing Algorithm
According to the FDA-approved prescribing information 11, the dosing schedule for adjunctive treatment of MDD follows this specific titration:
- Start: 0.5 mg or 1 mg once daily
- Week 1: Titrate to 1 mg once daily (if not already at this dose)
- Week 2+: Increase to target dose of 2 mg once daily based on clinical response and tolerability
- Maximum dose: 3 mg once daily
The target therapeutic dose is 2 mg once daily 112. This can be administered with or without food 1.
Evidence Supporting the 2 mg Target Dose
Multiple randomized controlled trials demonstrate that 2 mg daily is the optimal dose for balancing efficacy and tolerability:
- In pooled Phase III trials, brexpiprazole 2 mg showed significant improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo (treatment effect -2.47 points, p<0.001) 23
- Meta-analysis data indicate that doses ≤2 mg/day at 6 weeks provide a better risk/benefit balance than higher doses, with lower rates of akathisia (RR=2.28 vs 4.58) and somnolence while maintaining efficacy 4
- The number needed to treat (NNT) for response at the recommended 2 mg dose is 12, indicating clinically meaningful benefit 5
Important Titration Considerations
Slow titration over 1-2 weeks to the target dose is essential 65. This gradual approach minimizes activation-related adverse effects, particularly akathisia, which occurred in 8.6% of MDD patients in clinical trials 15.
Dose Modifications Required For:
- Hepatic impairment (Child-Pugh ≥7): Maximum 2 mg daily 11
- Renal impairment (CrCl <60 mL/min): Maximum 2 mg daily 11
- CYP2D6 poor metabolizers or concurrent strong CYP3A4/CYP2D6 inhibitors: Dose reduction required 1
Clinical Context
Brexpiprazole is indicated specifically as adjunctive therapy to antidepressants in adults with MDD who have inadequate response to antidepressant treatment alone 11. The ACP guidelines support selecting between cognitive behavioral therapy or second-generation antidepressants for initial MDD treatment 77, with adjunctive agents like brexpiprazole reserved for inadequate responders.
Common Pitfalls to Avoid
- Do not start at 2 mg: Beginning at the target dose increases akathisia risk
- Do not use as monotherapy: Brexpiprazole is FDA-approved only as adjunctive treatment with an antidepressant for MDD 11
- Do not exceed 3 mg daily: Higher doses increase adverse effects without additional efficacy benefit 4
- Monitor within 1-2 weeks: Early assessment for suicidality, akathisia, and tolerability is critical 88
The most common adverse effects at therapeutic doses include weight gain (8.0%), akathisia (8.6%), and gastrointestinal symptoms 12.